BioFactura Awarded US Patent for its StableFast™ Biomanufacturing Platform
22 NOV 2011
BioFactura was awarded a US patent covering the core technologies of its proprietary StableFast™ Biomanufacturing Platform.
The US Patent and Trademark Office allowed 32 claims broadly covering composition of matter, methods, commercial kits, and media
formulations. StableFast™ was commercially launched earlier this year. The Company is actively marketing the system to companies
developing biopharmaceuticals including novel compounds and biosimilars with a focus on therapeutic monoclonal antibodies.
“This patent represents years of innovation and development by the BioFactura team that includes the Company's original founders,”
said Darryl Sampey, BioFactura’s President and CEO. “I’d also like to acknowledge the excellent work of our intellectual property
legal team at Womble Carlyle. We are proud that the USPTO has allowed such a broad set of claims, and we look forward to bringing
the StableFast™ platform to a range of clients in the private and government sectors seeking to develop and manufacture tomorrow’s
lifesaving drugs.”
BioFactura Receives a $244,479 Qualifying Therapeutic Discovery Project Grant
04 NOV 2010
BioFactura was awarded a grant totaling approximately $244, 479 under the Qualifying Therapeutic Discovery Project (QDTP)
of the Patient Protection and Affordable Care Act of 2010 for its Smallpox Biodefense Therapeutic. The grant is a benefit targeted
to small business therapeutic discovery projects that show a potential to result in new therapies that treat or prevent diseases
or conditions representing unmet medical needs, reduce long-term health care costs in the U.S., and demonstrate the potential to
enhance U.S. competitiveness and create high quality jobs in the U.S.
Bioterrorism has been labeled a “Clear and Present Danger” by the US government and smallpox has been determined to be among
the highest priority threats. At the present time there is no approved treatment for smallpox exposure or active infection. Although
effective licensed vaccines against smallpox are available, there are risks of serious, life-threatening infection in certain
individuals who receive the vaccine. Through its Smallpox Biodefense Therapeutic Program, BioFactura is developing a monoclonal
antibody (mAb) based therapeutic that will treat adverse smallpox vaccination events and aims to treat other pathogenic poxvirus
infections such as smallpox. Advanced drug development is supported by a collaboration with the United States Army Medical
Research Institute of Infectious Diseases (USAMRIID) and support from the National Institutes of Health (NIH).
Darryl Sampey, President and CEO of BioFactura stated, “We are pleased that BioFactura was selected as a recipient for this grant
as we continue preclinical efficacy and safety studies that will lead to clinical testing of the Smallpox Biodefense Therapeutic.”